Investor presentation ContextVision – Interview with Nordnet
Nordnet have published an investor presentation of ContextVision. Please find the interview with CEO Fredrik Palm below (in Norwegian/Swedish) or follow this link.
ContextVision – Second quarter saw commercial release of first AI-based product, Altumira™, Digital Pathology on track and record sales
STOCKHOLM – August 15, 2019 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, continued to advance its artificial intelligence portfolio in the second quarter 2019. The company’s AI-based product Altumira™ for X-ray is now commercially available and INIFY Prostate for digital pathology will soon move to beta testing in […]
ContextVision’s Deep Learning experts will hold an oral presentation at the Medical Imaging & Deep Learning conference in London July 8–10
This paper presents an interesting and novel idea of a deep learning (DL) framework to segment potentially cancerous areas in prostate biopsies using semi-automatically generated data. The application of this paper is quite innovative and the proposed method seems to be a direct assistance to the clinical routine.
ContextVision sees strong sales, continues focus on launch of AI-based digital pathology
ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, reported strong sales in Q1, reaching 21.1 MSEK, 9% higher than the first quarter last year. The company reports positive feedback from user tests within digital pathology and continues to proceed with product development for this fast-growing market.
ContextVision Earns Acclaim from Frost & Sullivan for Its AI-powered INIFY™ Prostate Cancer Screening Platform
Based on its recent analysis of the European prostate cancer screening market, Frost & Sullivan recognises the Stockholm-based ContextVision AB with the 2019 European Technology Leadership Award for its INIFY™ Prostate platform.
ContextVision signs agreement for research based on unique big data cohorts
ContextVision will have exclusive rights to the scanning cohort and access to anonymized associated clinical data - with cleared and structured histopathological descriptions, diagnosis and outcome data - for the defined patient cohorts and all commercial rights from output based on the data.The agreement gives ContextVision an opportunity to create AI-based decision support tools that will help doctors make more accurate treatment decisions. Today, many cancer patients suffer from life impairing side effects from treatments they did not need while other patients do not get treatment which is necessary.
ContextVision – Fredrik Palm appointed new CEO
STOCKHOLM – 27. of March 2019 – ContextVision, a medical technology company specializing in image analysis and artificial intelligence, is pleased to announce that Fredrik Palm will become CEO of the Company as of April 1, 2019. Fredrik Palm has since 2012 been the Company’s V.P. of sales and was instrumental in growing sales significantly under his […]
ContextVision – Company presentation held at Danske Bank Small & Mid Cap Seminar in Stockholm
Today ContextVision held a company presentation at Danske Bank's Small & Mid Cap Seminar in Stockholm, Sweden.CEO Anita Tollstadius gave an update of the company's development and shared the company's future direction.
Context Vision skapar nya lösningar med hjälp av AI – appearance in online magazine Investeringstipset
An update on ContextVision has been published in the Swedish online magazine Investeringstipset.
ContextVision to showcase Altumira(TM), AI-powered image enhancement for digital radiography at ECR 2019
With deep learning technology integrated, Altumira is specially designed to meet the demanding needs of digital radiography for both dynamic and static X-ray. At ECR, the full suite of industry-leading image enhancement products for ultrasound will be showcased. ContextVision's products deliver unsurpassed image quality for all types of ultrasound systems from handheld devices to the most advanced 3D/4D applications.